Patents by Inventor MATHIEU KERBIRIOU

MATHIEU KERBIRIOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and pharmaceutical compositions for the treatment of diseases associated with reduced CFTR function
    Patent number: 11458118
    Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 4, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE BRETAGNE OCCIDENTALE, ETABLISSEMENT FRANÇAIS DU SANG (EFS), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST
    Inventors: Pascal Trouve, Claude Ferec, Mathieu Kerbiriou, Florentin Huguet
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTION
    Publication number: 20200121642
    Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 23, 2020
    Inventors: PASCAL TROUVE, CLAUDE FEREC, MATHIEU KERBIRIOU, FLORENTIN HUGUET